Drug · DIN 02538741
XCOPRI
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since December 19, 2025; first marketed November 20, 2023.
- Drug Identification Number (DIN)
- 02538741
- Company (DIN owner)
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Cenobamate N03AX25
- Class
- Human
- Record last updated
- December 29, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CENOBAMATE | 150 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 19, 2025: NOC 36581New Drug Submission (NDS) · Administrative: Change in product ownership
- June 12, 2023: NOC 30970New Drug Submission (NDS)
Other DINs named XCOPRI
- DIN 02538652 · Marketed
- DIN 02538660 · Marketed
- DIN 02538725 · Marketed
- DIN 02538733 · Marketed
- DIN 02538768 · Marketed
- DIN 02538776 · Marketed
- DIN 02538784 · Marketed
- DIN 02538792 · Approved
- DIN 02538806 · Approved
- DIN 02538814 · Approved